long intergenic non-protein coding RNA 1710Genealiases: []
Q-omics provides the consensus-scored LINC01710 profile across patient tissues and cancer cell-line models. LINC01710 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, LINC01710 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, LINC01710 RNA expression shows 12,830 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight READ, KIRC, and THYM as cancer lineages where LINC01710 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01710 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01710 survival associations across molecular data types. LINC01710 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01710 RNA expression–survival associations across cancer types. High LINC01710 expression shows unfavorable associations in READ, DLBC, BLCA, CHOL, STAD and LIHC. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for LINC01710 RNA expression.
This table summarizes LINC01710 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01710. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01710 shows lower tumor expression in KIRC, BRCA, KICH, UCEC, PRAD and KIRP. The KIRC box plot shows higher LINC01710 RNA expression in normal versus tumor tissue (log2 FC = −0.115, t-test p < 0.001).
This table shows molecular features associated with LINC01710 in patient tissues and cancer cell lines. In patient samples, LINC01710 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
